Ozempic

Ozempic. It is a glucagon-like peptide-1 receptor agonist medication developed by the Danish pharmaceutical company Novo Nordisk for the treatment of type 2 diabetes. The active ingredient, semaglutide, mimics an incretin hormone to enhance insulin secretion and suppress glucagon release. Its use has expanded significantly due to its pronounced effects on body weight and cardiovascular outcomes, leading to widespread clinical and societal impact.

Medical uses

Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is approved by regulatory bodies like the U.S. Food and Drug Administration and the European Medicines Agency for this purpose. Clinical evidence supports its use to reduce the risk of major cardiovascular events such as myocardial infarction and stroke in patients with type 2 diabetes and established cardiovascular disease. The SUSTAIN clinical trial program provided foundational data for these approvals, demonstrating significant reductions in hemoglobin A1c and body weight.

Adverse effects

The most common adverse reactions associated with Ozempic involve the gastrointestinal tract, including nausea, vomiting, diarrhea, abdominal pain, and constipation. These effects are typically dose-dependent and often transient. More serious potential risks include pancreatitis, diabetic retinopathy complications, gallbladder disease, and acute kidney injury. The medication carries a boxed warning from the FDA regarding the risk of thyroid C-cell tumors, based on findings in rodent studies; its use is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in those with Multiple Endocrine Neoplasia syndrome type 2.

Pharmacology

Semaglutide, the active component of Ozempic, is a GLP-1 analog with 94% sequence homology to human GLP-1. It acts as a potent and selective agonist at the GLP-1 receptor, which is expressed in pancreatic islets, the heart, and the central nervous system. Its mechanism involves glucose-dependent stimulation of insulin secretion from pancreatic beta cells and suppression of glucagon secretion from pancreatic alpha cells. It also slows gastric emptying and promotes satiety through direct action on the hypothalamus. The drug is formulated with an acyl side chain that promotes binding to albumin, extending its half-life to approximately one week and allowing for once-weekly subcutaneous administration.

History and society

Ozempic was developed by researchers at Novo Nordisk's facilities in Bagsværd, Denmark, building upon the company's earlier work with the GLP-1 analog liraglutide. It received its first global approval from the FDA in December 2017. The drug's significant secondary effect of promoting weight loss, confirmed in the STEP clinical trial program for obesity, led to an unprecedented surge in demand, creating global supply shortages. This phenomenon attracted widespread media coverage in outlets like The New York Times and CNN, and sparked complex debates about healthcare access, medicalization of obesity, and its off-label use for cosmetic weight loss, often highlighted by celebrities on platforms like TikTok.

Clinical trials

The efficacy and safety of Ozempic were established in the multinational SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) phase 3 clinical trial program, which involved over 10,000 participants across studies like SUSTAIN 6. These trials, often presented at the American Diabetes Association Scientific Sessions, demonstrated superior reductions in HbA1c and body weight compared to placebos and active comparators like sitagliptin and insulin glargine. The landmark SUSTAIN 6 trial further showed a significant reduction in the risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, leading to an expanded indication. Subsequent trials, including PIONEER for an oral formulation and SELECT for cardiovascular outcomes in patients with obesity, have further elucidated its broad therapeutic profile.

Category:Antidiabetic drugs Category:Novo Nordisk